Shots:

• The P-III study evaluates the efficacy and safety of VV116 vs SOC in subjects with moderate to severe COVID-19. The 1EPs of the study is the percentage of patients who progress to critical COVID-19 patients or all-cause mortality within 29days
• Additionally, Junshi and Vigonvita also initiated P-II/III study that evaluates the efficacy, safety and PK of VV116 in the early treatment of mild to moderate COVID-19 patients. The first patient has been enrolled and dosed in China
• The companies have completed three P-I studies evaluating the safety, tolerability & PK of VV116 in healthy Chinese subjects, with preliminary results demonstrating good clinical safety

Ref: Globe Newswire | Image: Junshi